Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 187

Results For "GE"

8961 News Found

Philips launches game-changing interventional platform for cardiology
News | March 29, 2026

Philips launches game-changing interventional platform for cardiology

IntraSight Plus enables confident decision-making and better patient care,” Philips said, emphasizing efficiency, simplicity, and precision


Novartis acquires Excellergy to bolster allergy portfolio
News | March 28, 2026

Novartis acquires Excellergy to bolster allergy portfolio

The move leverages Novartis’ deep expertise in IgE biology and long-standing presence in allergic disease treatments


Eli Lilly drug shows 4-year relief for eczema patients, study finds
R&D | March 28, 2026

Eli Lilly drug shows 4-year relief for eczema patients, study finds

The therapy works by targeting interleukin-13, a key driver of inflammation behind eczema symptoms such as itching, skin damage, and infection


Otsuka Pharma to acquire Transcend Therapeutics in $1.225 billion deal
News | March 28, 2026

Otsuka Pharma to acquire Transcend Therapeutics in $1.225 billion deal

Otsuka will pay $700 million to Transcend shareholders at closing, with an additional $525 million in contingent payments tied to future sales milestones


Shreehas Tambe appointed CEO & Managing Director of Biocon
People | March 28, 2026

Shreehas Tambe appointed CEO & Managing Director of Biocon

Kedar Upadhye has also been appointed as Chief Financial Officer of Biocon Limited


AbbVie stakes claim to redefine skin disease treatment at Global Dermatology Summit
R&D | March 28, 2026

AbbVie stakes claim to redefine skin disease treatment at Global Dermatology Summit

Beyond clinical trials, real-world evidence is adding weight to AbbVie’s claims


AstraZeneca’s breakthrough COPD drug Tozorakimab slashes flare-ups in landmark Phase III trials
Clinical Trials | March 28, 2026

AstraZeneca’s breakthrough COPD drug Tozorakimab slashes flare-ups in landmark Phase III trials

High-level results from the Phase III OBERON and TITANIA trials revealed that the first-in-class monoclonal antibody reduced the annual rate of moderate-to-severe COPD exacerbations compared with placebo


Lonza launches Singapore Media Development Lab to cut biomanufacturing risk
R&D | March 27, 2026

Lonza launches Singapore Media Development Lab to cut biomanufacturing risk

The move comes as drug developers face mounting pressure from faster timelines and increasingly complex manufacturing processes


HDFC Bank, Smile Foundation launch 8 mobile medical units to serve 4 lakh in remote north India
Healthcare | March 27, 2026

HDFC Bank, Smile Foundation launch 8 mobile medical units to serve 4 lakh in remote north India

The programme aims to provide critical healthcare services to approximately 4 lakh people in remote and resource-scarce communities


CuraTeQ Biologics enters into agreement with STADA Arzneimittel AG
News | March 27, 2026

CuraTeQ Biologics enters into agreement with STADA Arzneimittel AG

STADA will market and distribute two EMA approved biosimilars developed by CuraTeQ in select European Union territories